Categories Health Care, IPO, Others
IPO News: What to look for when Healthcare Triangle goes public
The company looks to raise around $46 million by offering its common shares at an estimated price between $4.50 and $5.50 per share
The global healthcare information technology market was valued at $74.2 billion in 2020, and it is expected to grow at a compound annual rate of 10.7% over the next seven years. The growing demand for medical information solutions is driving emerging players in that segment to public markets as they seek to expand their businesses. Joining the IPO spree, Healthcare Triangle Inc. recently revealed plans to go public.
To Raise $46 Mln
The Pleasanton, California-based company provides AI-enabled information solutions to healthcare firms for performance optimization and digital transformation. It plans to offer around 9.2 million shares at an estimated price between $4.50 and $5.50 per share. At the mid-point of the price range, the offering is expected to generate net proceeds of around $46.4 million.
Read management/analysts comments on quarterly reports
The stock will trade at the Nasdaq Capital Market under the ticker symbol HCTI after obtaining the green signal from the Securities and Exchange Commission. The sole bookrunner in the offering is ED Hutton. The management intends to use proceeds from the offering for strategic acquisitions, debt repayment, and working capital/general corporate purposes.
High Demand
Since the onset of the pandemic, the healthcare and life sciences industry has been witnessing rapid adoption of digital communication channels and remote working technology, which bodes well for companies like Healthcare Triangle. Going forward, the main challenges facing the company would be to ensure adequate data security and to deal with the pandemic-induced disruption and continuing uncertainty effectively.
Currently led by chief executive officer Suresh Venkatachari, Healthcare Triangle was founded in 2019 to offer a slew of technology solutions including healthcare IT managed services, blockchain infrastructure, and data lifecycle management. The company’s solutions and software platforms CloudEz and DataEz help healthcare companies offer personalized care and precision medicine, and allows pharma firms to optimize their R&D initiatives and drug discovery.
CloudEz, which is a software-as-a-service offering designed to provide frameworks for healthcare organizations to build self-service platforms, and DataEz — a cloud-based solution for life sciences and healthcare organizations to enhance their data platforms — were launched a few months ago.
Revenue up 20%
In the three months ended June 2021, Healthcare Triabgle’s revenues grew 20% year-over-year to $18 million. However, its net loss widened to $511.4 million from $338.2 million in the corresponding period of 2020 mainly owing to an increase in operating costs.
iFIT Health & Fitness to raise $600 mln in IPO. Here’s what you need to know
Medical device maker Minerva Surgical, another emerging healthcare solutions company based in the Bay Area, filed for an initial public offering this week, targeting to raise around $100 million.
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company